Protara Therapeutics, Inc.TARANASDAQ
LOADING
|||
Operating Income Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year operating income growth rate
Latest
11.01%
↑ 162% above average
Average (39q)
-17.75%
Historical baseline
Range
High:208.53%
Low:-497.65%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 11.01% |
| Q2 2025 | -17.43% |
| Q1 2025 | 1.31% |
| Q4 2024 | -16.07% |
| Q3 2024 | -15.66% |
| Q2 2024 | 10.04% |
| Q1 2024 | -7.34% |
| Q4 2023 | -3.19% |
| Q3 2023 | 11.86% |
| Q2 2023 | -24.74% |
| Q1 2023 | 75.37% |
| Q4 2022 | -395.47% |
| Q3 2022 | 8.40% |
| Q2 2022 | 19.95% |
| Q1 2022 | -5.71% |
| Q4 2021 | 5.01% |
| Q3 2021 | 15.34% |
| Q2 2021 | 5.80% |
| Q1 2021 | -51.62% |
| Q4 2020 | -11.09% |
| Q3 2020 | -10.96% |
| Q2 2020 | 28.49% |
| Q1 2020 | -497.65% |
| Q4 2019 | 208.53% |
| Q3 2019 | -64.77% |
| Q2 2019 | 6.50% |
| Q1 2019 | -8.61% |
| Q4 2018 | 69.56% |
| Q3 2018 | 7.56% |
| Q2 2018 | 21.51% |
| Q1 2018 | -13.95% |
| Q4 2017 | 54.59% |
| Q3 2017 | -105.51% |
| Q2 2017 | 7.56% |
| Q1 2017 | 5.68% |
| Q4 2016 | 4.18% |
| Q3 2016 | 8.66% |
| Q2 2016 | -15.10% |
| Q1 2016 | -10.18% |
| Q4 2015 | -21.85% |